We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva (TEVA): Can it Keep the Earnings Streak Alive in Q3?
Read MoreHide Full Article
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) will be reporting third-quarter 2016 earnings on Nov 15, before market open. Last quarter, the company delivered a positive earnings surprise of 5.93%.
The generic drug maker has been consistently beating earnings expectations. The company’s earnings surpassed expectations in three of the last four quarters, with an average positive surprise of 3.75%.
Let’s see how things are shaping up for this announcement.
Factors to Consider
Teva’s generic segment could continue seeing weakness. In the first and second quarters, generic segment revenues declined 17% and 7%, respectively. Revenues from U.S. generics declined more than 30% in both the quarters reflecting loss of exclusivity for the generic versions of Nexium and Pulmicort.
In the third quarter, important launches were that of generic versions of Cubicin and Gleevec in the U.S. which can provide some sales support.
The EU generics segment will remain under pressure with sales being affected by macro-economic conditions and healthcare reforms.
However, Teva’s position in the generics market should strengthen with the completion of the acquisition of Allergan plc’s generics segment -- Actavis Generics in August and its U.S. generic distribution business Anda, Inc. in October.
With the closing of this deal, Teva now has commercial presence in 80 markets, including a top-three leadership position in more than 40 markets and global leadership in all key global markets. The combined pending ANDAs are about 338 including 115 FTFs and Teva now has a significantly improved platform in the EU and ROW. Meanwhile, Allergan’s Anda business will be a natural fit in Teva's business model.
Teva expects to achieve $1.4 billion in operational and tax synergies by the end of 2019 through this deal which is expected to boost 2017 EPS by about 17% and 2019 EPS by 19%.
Meanwhile, in the branded segment, specialty products and Copaxane should continue to do well.
Investors will remain focused on the Copaxone franchise’s performance considering the 20 mg version of the multiple sclerosis treatment that is facing generic competition in the form of Glatopa. Investors will also be interested in the performance of newly launched products like Bendeka and Cinqair.
Teva continues to focus on its cost reduction program which should pull up profits.
Earnings Whispers
Our proven model does not conclusively show that Teva is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: The Earnings ESP is -0.79% as the Most Accurate estimate stands at $1.26 per share while the Zacks Consensus Estimate is pegged higher at $1.27 per share.
Zacks Rank:T eva’s Zacks Rank #3 increases the predictive power of ESP. However, we need to have a positive ESP to be confident about an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter
We caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter:
Global Blood Therapeutics, Inc. with an Earnings ESP of +16.95% and a Zacks Rank #2. The company is expected to release results on Nov 10.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teva (TEVA): Can it Keep the Earnings Streak Alive in Q3?
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) will be reporting third-quarter 2016 earnings on Nov 15, before market open. Last quarter, the company delivered a positive earnings surprise of 5.93%.
The generic drug maker has been consistently beating earnings expectations. The company’s earnings surpassed expectations in three of the last four quarters, with an average positive surprise of 3.75%.
TEVA PHARM ADR Price and EPS Surprise
TEVA PHARM ADR Price and EPS Surprise | TEVA PHARM ADR Quote
Let’s see how things are shaping up for this announcement.
Factors to Consider
Teva’s generic segment could continue seeing weakness. In the first and second quarters, generic segment revenues declined 17% and 7%, respectively. Revenues from U.S. generics declined more than 30% in both the quarters reflecting loss of exclusivity for the generic versions of Nexium and Pulmicort.
In the third quarter, important launches were that of generic versions of Cubicin and Gleevec in the U.S. which can provide some sales support.
The EU generics segment will remain under pressure with sales being affected by macro-economic conditions and healthcare reforms.
However, Teva’s position in the generics market should strengthen with the completion of the acquisition of Allergan plc’s generics segment -- Actavis Generics in August and its U.S. generic distribution business Anda, Inc. in October.
With the closing of this deal, Teva now has commercial presence in 80 markets, including a top-three leadership position in more than 40 markets and global leadership in all key global markets. The combined pending ANDAs are about 338 including 115 FTFs and Teva now has a significantly improved platform in the EU and ROW. Meanwhile, Allergan’s Anda business will be a natural fit in Teva's business model.
Teva expects to achieve $1.4 billion in operational and tax synergies by the end of 2019 through this deal which is expected to boost 2017 EPS by about 17% and 2019 EPS by 19%.
Meanwhile, in the branded segment, specialty products and Copaxane should continue to do well.
Investors will remain focused on the Copaxone franchise’s performance considering the 20 mg version of the multiple sclerosis treatment that is facing generic competition in the form of Glatopa. Investors will also be interested in the performance of newly launched products like Bendeka and Cinqair.
Teva continues to focus on its cost reduction program which should pull up profits.
Earnings Whispers
Our proven model does not conclusively show that Teva is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: The Earnings ESP is -0.79% as the Most Accurate estimate stands at $1.26 per share while the Zacks Consensus Estimate is pegged higher at $1.27 per share.
Zacks Rank:T eva’s Zacks Rank #3 increases the predictive power of ESP. However, we need to have a positive ESP to be confident about an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter
We caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter:
AveXis, Inc. is scheduled to release results on Nov 10. The company has an Earnings ESP of 11.43% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Global Blood Therapeutics, Inc. with an Earnings ESP of +16.95% and a Zacks Rank #2. The company is expected to release results on Nov 10.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>